Ipsen

Pharma

Ipsen's liver disease drug Bylvay fails biliary atresia trial

Ipsen has reported the failure of liver disease med Bylvay in a phase 3 study that was designed to expand its patient population into biliary atresia.

Kevin Dunleavy Jul 24, 2026 11:00am

Ipsen’s Botox rival Dysport posts dual ph. 3 wins in migraine

Jul 9, 2026 10:36am

With trial success, Gilead paves way for broader use of Livdelzi

Jun 2, 2026 10:55am

18th birthday cupcake teenager young adult

Ipsen details growing pains as teens transition to adult care

May 20, 2026 11:51am

Safety signals prompt Ipsen to withdraw cancer med Tazverik

Mar 9, 2026 10:07am

China biotech deals, Shionogi's ALS buy—Fierce Pharma Asia

Jan 9, 2026 3:00am